Antibiotic Add-On Active in Crohn’s Disease – More evidence for a mycobacterial origin

This is an excellent explanation of the results from Redhill Biopharma’s trial of RHB-104, a formulation of three antibiotics against MAP to treat Crohn’s disease. All research in this area is very welcome as we head into phase 2 trial of the Crohn’s MAP Vaccine.

https://www.medpagetoday.com/meetingcoverage/acg/83055?fbclid=IwAR3n_8ds0-LnxeTt9u4oNYQfxzLJDuncGul6sDBdxO-mWb_vfct_EUfougY